Overview

Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Ravulizumab in Chinese Adults Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2026-01-14
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the efficacy of ravulizumab in adult participants with PNH.
Phase:
PHASE3
Details
Lead Sponsor:
Alexion Pharmaceuticals, Inc.
Treatments:
ravulizumab